Cost-utility analysis is used within the health technology assessment processes of many countries. For these analyses, patients typically indicate the health state that they are in based on a pre-defined descriptive classification. Each health state corresponds to a utility value; these values...

Background: Trastuzumab has significantly improved survival outcomes for women with HER2 positive early breast cancer. Trastuzumab was established as a costeffective adjuvant treatment in 2006. We present an updated cost-effectiveness analysis from the UK perspective which explores assumptions...

The National Institute for Health and Clinical Excellence (NICE) has been using a cost-effectiveness threshold range between Lstg 20_000 and Lstg 30_000 for over 7 years. What the cost-effectiveness threshold represents, what the appropriate level is for NICE to use, and what the other factors...

Objective: The objective of this study was to conduct an economic evaluation to identify any differences in the expected costs and outcomes between patients treated with pulmonary artery catheters (PACs) and those without, in order to better inform healthcare decision makers. Method: The...

In a recent leading article in PharmacoEconomics, Nuijten described some methods for incorporating uncertainty into health economic models and for utilising the information on uncertainty regarding the cost effectiveness of a therapy in resource allocation decision-making. His proposals are...